{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-017214","form_type":"8-K","ticker":"AURX","cik":"0001091596","company_name":"Nuo Therapeutics, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.484389+00:00","generated_at":"2026-05-21T04:29:28.931530+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Nuo Therapeutics enters interim sales agency agreement with Smith+Nephew for Aurix products","bullets":["Amendment to Distribution Agreement grants Smith+Nephew interim sales agent role for Nuo Aurix brand to certain Smith+Nephew customers.","Smith+Nephew receives commission on net sales of Nuo branded products sold to its customers under interim arrangement.","Interim agency terminates by Dec 31, 2025 or earlier with 30 days written notice.","Underlying five-year Distribution Agreement for Nuo to supply private-label Aurix to Smith+Nephew remains in effect."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-017214","json":"https://secwatch.observer/filing/0001437749-25-017214.json","markdown":"https://secwatch.observer/filing/0001437749-25-017214.md","text":"https://secwatch.observer/filing/0001437749-25-017214.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1091596/000143774925017214/0001437749-25-017214-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1091596/000143774925017214/aurx20250514_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:29:28.931530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}